Progress on the pathogenesis and treatment of IgG4-related disease
10.16438/j.0513-4870.2022-0074
- VernacularTitle:IgG4相关疾病发病机制及治疗进展
- Author:
Xing JI
;
Chen-yang LU
;
Ping-ying QING
;
Yi ZHAO
;
Yi LIU
;
Chun-yu TAN
;
Yu-bin LUO
- Publication Type:Research Article
- Keywords:
IgG4-related disease;
pathogenesis;
autoimmunity;
fibrosis;
treatment;
biological agent
- From:
Acta Pharmaceutica Sinica
2022;57(8):2283-2291
- CountryChina
- Language:Chinese
-
Abstract:
IgG4-related disease (IgG4-RD) is a newly recognized fibro-inflammatory condition of autoimmune etiology in recent twenty years, mainly manifesting as mass-forming lesions in single or multiple organs. In the past, it was often missed or misdiagnosed as inflammation or tumor. Patients may die from multiple organ failure due to end-stage fibrosis if they are not treated promptly. However, the number of clinically confirmed cases has gradually increased with the improvement of diagnostic level in recent years, and these patients have benefited greatly after receiving early treatment. Although patients generally respond well to traditional immunosuppressors including glucocorticoids and disease-modifying anti-rheumatic drugs, refractory and recurrent cases, even patients with glucocorticoid contraindication are common. Important mechanistic insights have been derived from studies of B-cell depletion therapy, but greater awareness of the pathophysiology of IgG4-RD is still badly needed to identify novel therapeutic targets. In this article, we reviewed the pathogenesis progress and promising therapy of IgG4-RD to seek better clinical management of IgG4-RD.
